Skip to content
CompoundSci
All briefs

Metabolic

GLP-1 Receptor Agonists: The Mechanism, The Trials, The Trade-offs

Semaglutide, tirzepatide and what comes next, incretin biology, the actual trial numbers, and the questions the headlines skip.

13 min read
Medical researcher reviewing metabolic study data on a screen

Want to listen instead of read?

Log in or create a free account to play this narration (about 13 min) and listen to dozens of peptide research briefs, hands free.

Log in to listenCreate a free account

GLP-1 receptor agonists went from a niche diabetes class to the most consequential metabolic drugs of the decade. The science is genuinely strong, which makes it worth understanding precisely, rather than through headlines.

14.9%

Mean weight reduction

Semaglutide 2.4 mg, STEP 1, 68 weeks

20.9%

Mean weight reduction

Tirzepatide 15 mg, SURMOUNT-1, 72 weeks

20%

Reduction in major adverse cardiac events

SELECT trial, non-diabetic population

The incretin effect, in one paragraph

Glucose taken by mouth triggers far more insulin release than the same amount of glucose infused intravenously. The difference is the incretin effect, and GLP-1 is one of the two hormones responsible. It is secreted by L-cells in the distal gut, potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and acts on hypothalamic and hindbrain circuits to reduce food intake.

Why the analogues last and native GLP-1 does not

Native GLP-1 has a half-life of one to two minutes because DPP-4 clips it almost immediately. Every clinically useful agonist solves that problem structurally: amino acid substitution at position 8 to block DPP-4, plus a fatty-acid chain that binds albumin and creates a circulating depot.

Structural strategies across the class

AgentReceptor targetsDosing intervalKey structural trick
LiraglutideGLP-1DailyC16 palmitic acid via glutamate spacer
SemaglutideGLP-1WeeklyAib at position 8 plus C18 diacid linker
TirzepatideGIP and GLP-1WeeklyDual agonist backbone with C20 diacid
RetatrutideGIP, GLP-1, glucagonWeeklyTriple agonism including energy expenditure arm

Free · no spam

One email, every Tuesday

The metabolic and peptide literature that actually moved this week, with the effect sizes attached.

What the trials measured, and what they did not

STEP and SURMOUNT were weight endpoints. SELECT was cardiovascular. FLOW was renal. None of them were body-composition trials, which is why the lean-mass question is answered mostly by DEXA substudies with small numbers, roughly a quarter to a third of lost mass is lean tissue, in line with other caloric-deficit interventions but not obviously better.

Questions readers keep asking

Do GLP-1 agonists cause muscle loss?

They cause weight loss, and weight loss always includes lean mass. Substudy data puts the lean fraction near 25–40%, comparable to diet-driven loss. Resistance training and adequate protein are the studied mitigations.

What about gastroparesis?

Delayed gastric emptying is the mechanism, not a side effect. Clinically significant gastroparesis is a documented but uncommon adverse event; pharmacovigilance signals exist and are being examined.

Is compounded semaglutide the same molecule?

Not necessarily. Several compounded products have used salt forms not shown to be equivalent, and independent testing has found variable content.

Reference

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding JPH, et al. · New England Journal of Medicine · 2021

STEP 1. The 68-week trial that established the 14.9% mean reduction figure.

Reference

Tirzepatide Once Weekly for the Treatment of Obesity

Jastreboff AM, et al. · New England Journal of Medicine · 2022

SURMOUNT-1, dual GIP/GLP-1 agonism at up to 20.9% mean reduction.

Reference

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Lincoff AM, et al. · New England Journal of Medicine · 2023

SELECT. The trial that moved the class from metabolic to cardiovascular medicine.

Start a conversation

Debate this

Peptide science moves faster than the consensus around it. Post it with a question and see what people who disagree with you have to say.

Does the research here match what you have seen in practice?

This question is attached to your post, along with a link back to the brief.

Tip: highlight any sentence in the article to debate that exact line.

Read next